SPX LABS • RESEARCH LIBRARY

Peptides Craze: But What Does the Science Say?

What do peptide research studies actually show? This evidence-led guide examines published human and animal results behind SPX Labs catalogue materials, separating direct findings from early or indirect evidence.

Published by SPX Labs Research Editorial Team

The peptides craze is driven by a real scientific story, but the evidence is not uniform. These peptide research studies include direct human trial records for some SPX Labs catalogue materials, while others remain cell or animal-research topics. Treating all of them as though they have the same proof would be misleading.

This guide focuses on publicly listed SPX Labs research materials: tesamorelin, MOTS-C, CJC-1295 No DAC, ipamorelin, GHK-Cu, BPC-157 and TB-500. Retatrutide and bacteriostatic water are deliberately excluded.

Where a study reported a positive result, this article says what it measured. Where evidence is preclinical, indirect or mixed, it says that too. This is not medical advice and contains no dosing or administration information. It does not establish clinical equivalence for any SPX Labs research material, which is supplied only for legitimate in-vitro laboratory research, analytical testing and scientific evaluation—not for human or animal use.

One Word, Very Different Evidence Levels

Peptides are short chains of amino acids, but no two peptides automatically share a mechanism, evidence base or stage of development. A successful finding for one molecule is not proof for a molecule with a similar name, target or research area.

The useful way to read the field is to separate direct human evidence for the exact material studied, indirect human evidence for a related but non-identical material, and preclinical evidence from cells or animal models.

That approach lets readers appreciate real scientific progress without turning early laboratory observations into consumer promises.

What the Published Results Say at a Glance

This table keeps the important numbers attached to their study. It deliberately includes both positive and non-significant results: a useful scientific summary should show what a trial found, not only the figures that make the best headline.

The word versus below means the difference between groups assigned under that study’s protocol. It does not predict an individual result and does not apply to a separate research material.

Tesamorelin: The Strongest Direct Human Trial Record

Tesamorelin has the clearest direct human clinical record among the public SPX Labs catalogue materials discussed here. The pivotal Phase III research enrolled adults with HIV-associated lipodystrophy and used CT imaging to measure visceral adipose tissue—the deep abdominal fat depot specified in the protocol.

In one 26-week placebo-controlled study, visceral adipose tissue decreased by 15.2% in the tesamorelin group and increased by 5.0% in placebo. The report also recorded a 50 mg/dL fall in triglycerides in the tesamorelin group versus a 9 mg/dL rise with placebo, and an 81.0% rise in IGF-1 versus a 5.0% fall with placebo. A companion study reported a 10.9% reduction versus a 0.6% reduction with placebo.

The trial did not find every measure changed in the same direction. For example, the authors reported no significant difference between groups in glucose levels, while the scan-based, triglyceride and IGF-1 results differed. This is exactly why an honest article reports individual endpoints instead of saying a treatment ‘improved everything’.

In plain English: within these carefully selected clinical populations, the assigned trial-treatment groups had clearly different average scan and laboratory results from placebo at 26 weeks. The papers also recorded adverse events and withdrawals; these remain part of the result, not an optional footnote. None of this is a general body-composition claim or proof for an unrelated batch.

What the Tesamorelin Follow-Up Added

The longer-term record explains why follow-up matters. In an extension phase, participants who stopped the assigned study treatment did not retain the same visceral-adipose-tissue result observed during the controlled period. That is a study observation, not a use instruction.

A later 12-month randomised, double-blind trial enrolled 61 people with HIV and NAFLD; 30 received tesamorelin and 30 placebo. The primary outcome was hepatic-fat fraction measured by proton magnetic-resonance spectroscopy. The tesamorelin group had a 4.1 percentage-point greater absolute reduction than placebo, corresponding to a 37% relative reduction from baseline.

At 12 months, 35% of the tesamorelin group versus 4% of placebo had a hepatic-fat fraction below 5%. Fasting glucose and HbA1c changes did not differ between the groups, while local injection-site complaints were more frequent in the tesamorelin group. In layman’s terms: the study’s defined imaging measure differed between groups, but it did not show every laboratory measure moved in the same way.

MOTS-C: Positive Animal Research, Not a Human Trial Claim

MOTS-C is a mitochondrial-derived peptide available through the SPX Labs research catalogue. The original 2015 Cell Metabolism paper identified the 16-amino-acid peptide and investigated its biology in cell and mouse models.

The study included several separate mouse experiments. In one seven-day experiment, male C57BL/6 mice were assessed with a glucose-tolerance test (n=7) and clamp studies in high-fat-fed mice (n=6–8). In a longer high-fat-diet experiment, 8-week-old male CD-1 mice were studied for eight weeks (n=10). A shorter three-week high-fat-diet experiment used n=6.

The authors reported that MOTS-C treatment in those models prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity. Their measurements included glucose tolerance, glucose-infusion rate, insulin-stimulated glucose disposal, body weight, food and calorie intake, glucose and insulin levels, respiratory-exchange ratio and heat production.

In plain English: scientists saw a consistent direction of change across several metabolic measurements in the mice they studied. This is richer than a single before-and-after observation, but it remains animal research—not a human clinical trial or a human-use claim.

CJC-1295 No DAC: Why the ‘No DAC’ Detail Matters

CJC-1295 No DAC is publicly listed by SPX Labs, but the best-known early human CJC-1295 study examined a DAC-modified long-acting material. It comprised two randomised, double-blind, placebo-controlled ascending-dose trials lasting 28 and 49 days in healthy adults.

After a single assignment of the DAC-modified material, mean growth-hormone concentrations increased by 2- to 10-fold for six days or more, and mean IGF-1 increased by 1.5- to 3-fold for nine to 11 days. The authors estimated a 5.8- to 8.1-day half-life; after multiple assignments, mean IGF-1 remained above baseline for up to 28 days. No serious adverse reactions were reported in those early trials.

That is useful related-material evidence, but it is not direct human evidence for CJC-1295 No DAC. In layman’s terms: researchers could measure a prolonged hormone signal from the DAC-modified material; they did not test the No DAC material on the SPX catalogue.

Ipamorelin: Why an Honest Article Includes Mixed Results

Ipamorelin has experimental pharmacology research and an early human pharmacokinetic-pharmacodynamic literature. These studies helped researchers investigate receptor selectivity and hormone-release signalling in controlled conditions.

A later Phase II proof-of-concept trial tested ipamorelin in adults undergoing bowel resection. It was multicentre, randomised, double-blind and placebo-controlled. Its key endpoint was the time from first study assignment to tolerance of a standardised solid meal. The authors also assessed secondary recovery measures and adverse events.

Of 117 people enrolled, 114 formed the safety and modified intention-to-treat populations. Median time to first tolerated meal was 25.3 hours in the ipamorelin group and 32.6 hours in placebo, but this difference was not statistically significant (p=0.15). Any treatment-emergent adverse event was reported in 87.5% and 94.8% of the respective groups.

The authors’ conclusion was that there were no significant differences between ipamorelin and placebo in the key or secondary efficacy analyses. This is not a reason to hide the peptide from a research article. In layman’s terms: the measured time was numerically shorter in the ipamorelin group, but the study was not able to distinguish that difference from chance under its statistical test. A plausible mechanism and early signal still have to earn every clinical result.

GHK-Cu, BPC-157 and TB-500: Active Research, Different Boundaries

GHK-Cu, BPC-157 and TB-500 are widely discussed research materials, but their public evidence should not be treated as interchangeable. GHK-Cu has a long experimental literature around copper-peptide biology, while BPC-157 and TB-500 are represented principally by experimental, mechanistic and animal-model work in the literature commonly cited online.

The appropriate positive statement is that these remain active scientific subjects with experimental findings worth reading in their original context. It would be inaccurate to turn cell, tissue or animal observations into confirmed human therapeutic outcomes.

Researchers can use the literature to understand the questions being tested—such as signalling, tissue-model responses and peptide behaviour—while keeping the evidence level visible at every step.

Why a Published Study Does Not Validate a Separate Research Batch

A published paper describes its own study material, formulation, protocol and monitoring. It does not verify the identity, purity, stability, sterility or clinical equivalence of a separately supplied research material.

Clinical literature and analytical documentation therefore do different jobs. Trial reports explain what researchers observed in a defined study; batch-specific records concern a defined supplied sample and the method used to assess it. Neither substitutes for the other.

For SPX Labs materials, review the batch context and any associated documentation through the COA Library and Quality & Testing. A chromatographic result does not establish sterility, approval or human/veterinary suitability.

The Key Point to Remember

The peptide story has real positives. Tesamorelin has a substantial direct human trial record, MOTS-C has compelling foundational animal research, and the CJC-1295 and ipamorelin records show how researchers test a signalling hypothesis in human studies.

The strongest article is not one that says every peptide has the same evidence. It is one that celebrates the results the studies earned, states where the evidence is early or indirect and never turns published work into a promise for a separate research material.

Explore the SPX Labs Research Materials, then use the Research Library, Quality & Testing and COA Library to review the relevant research and documentation context.

Frequently Asked Questions